On October 1, 2019 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, reported that Natalie Holles, President and Chief Operating Officer, will participate in the following investor conferences in October (Press release, Audentes Therapeutics, OCT 1, 2019, View Source [SID1234539986]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chardan 3rd Annual Genetic Medicines Conference
Fireside Chat: Monday, October 7, 2019, at 10:30am ET
New York, New York

Jefferies Gene Therapy/Editing Summit
Fireside Chat: Tuesday, October 8, 2019, at 9:10am ET
Panel: "Manufacturing, Dose, and Durability in Gene Therapy," Tuesday, October 8, 2019, at 10:20am ET
New York, New York

To access live webcasts of the fireside chats, please visit the Events & Presentations page within the Investors + Media section of the Audentes website. Following each conference, a replay of the live webcast will be available on the Audentes website for approximately 30 days. There is no webcast available for the Manufacturing, Dose, and Durability in Gene Therapy panel at the Jefferies Gene Therapy/Editing Summit.